iSERA Lifescienc

Why is iSERA Lifesciences Ltd falling/rising?

As of 29-Aug, the stock price of iSERA Lifesciences Ltd is Rs. 143.90, unchanged from the previous session. Despite significant long-term gains, recent declines in trading activity and sector underperformance may be affecting the stock's price stability.

As of 29-Aug, the stock price of iSERA Lifesciences Ltd is currently at Rs. 143.90, showing no change from the previous trading session (0.00%). Despite the stock hitting a new 52-week high today, it has underperformed its sector by -1.05%. <BR><BR>In terms of performance metrics, the stock has experienced significant gains year-to-date, with an increase of 747.47%, and an impressive 3262.15% rise over the past year. However, the stock's recent performance indicates a decline in investor participation, as evidenced by a delivery volume of 100 on 27 August, which has fallen by -88.52% compared to the 5-day average. <BR><BR>Additionally, while the stock is trading above the 50-day, 100-day, and 200-day moving averages, it is below the 5-day and 20-day moving averages, suggesting a potential short-term weakness. The overall liquidity remains adequate for trading, but the drop in delivery volume may indicate a lack of investor interest, contributing to the stock's current stagnation in price. <BR><BR>In summary, while iSERA Lifesciences Ltd has shown remarkable long-term growth, the recent decline in trading activity and underperformance against its sector are factors that may be influencing the stock's price stability at this time.

Which are the latest news on iSERA Lifescienc?

Who are in the management team of iSERA Lifescienc?

The management team of iSERA Lifescienc includes K L Upadhyaya, Uday Chava, Srinivasa Rao Munnangi, Pittala Sukanya, Naresh Konda, Sakshi Mathur, Sivaiah Kommineni, and Prabhakara Rao Alokam, featuring a mix of independent directors and company executives.

The management team of iSERA Lifescienc includes the following individuals:<BR><BR>1. K L Upadhyaya - Independent Director<BR>2. Uday Chava - Independent Director<BR>3. Srinivasa Rao Munnangi - Independent Director<BR>4. Pittala Sukanya - Director<BR>5. Naresh Konda - Whole-time Director<BR>6. Sakshi Mathur - Company Secretary<BR>7. Sivaiah Kommineni - Additional Independent Director<BR>8. Prabhakara Rao Alokam - Director<BR><BR>This team comprises a mix of independent directors, directors, and a company secretary, contributing to the governance and management of the company.

What does iSERA Lifescienc do?

iSERA Lifesciences Ltd, formerly known as Covidh Technologies, operates in the IT/ITES sector as a Micro Cap company. As of June 2026, it reported no net profit and has a market cap of INR 121 Cr.

Overview:<BR>iSERA Lifesciences Ltd is engaged in the IT/ITES business and operates within the Miscellaneous industry, classified as a Micro Cap company.<BR><BR>History:<BR>The company was incorporated on January 27, 1993, originally as 'Lordven Technologies Limited'. It underwent name changes, first to Aptus Industries Limited in 2011-12 and then to Covidh Technologies Limited on April 21, 2014. The latest reported quarter for sales and profit is June 2026.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: 0 Cr (Quarterly Results - Jun 2026)<BR>Market-cap value: INR 121 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 237.00<BR>Industry P/E: 20<BR>Dividend Yield: 0.00%<BR>Debt-Equity: -1.61<BR>Return on Equity: -26.00%<BR>Price-to-Book: -121.01<BR><BR>Contact Details:<BR>Address: B-2 Plot 797/A Sai Krishna Bld, Road No 36 Jubilee Hills Hyderabad Telangana : 500033<BR>Phone: 91-040-64643093<BR>Email: cscovidh@gamil.com<BR>Website: http://www.covidh.co.in

Who are the peers of the iSERA Lifescienc?

iSERA Lifescienc's peers include Altius Telecom, Embassy Off.REIT, Mindspace Business, Inventurus Knowledge, Sagility, IDream Film, Kalpa Commercial, Focus Suites Solutions, and Amsons Apparels. iSERA Lifescienc has the highest 1-year return at 3875.14%, significantly outperforming its peers.

Peers: The peers of iSERA Lifescienc are Altius Telecom, Embassy Off.REIT, Mindspace Busine, Inventurus Knowl, Sagility, IDream Film, Kalpa Commer., Focus Suites Sol, and Amsons Apparels.<BR><BR>Quality Snapshot: Excellent management risk is observed at Inventurus Knowl, while Average management risk is found at Altius Telecom, Embassy Off.REIT, Mindspace Busine, Sagility, and the rest. Below Average management risk is noted for Kalpa Commer., while IDream Film, iSERA Lifescienc, Focus Suites Sol, and Amsons Apparels do not qualify. Excellent growth is seen at Inventurus Knowl, while Good growth is noted for Sagility, Average growth for Kalpa Commer., and Below Average growth for Embassy Off.REIT, Mindspace Busine, and the rest. IDream Film, iSERA Lifescienc, Focus Suites Sol, and Amsons Apparels do not qualify for growth. Excellent capital structure is present at Inventurus Knowl and Sagility, while Below Average capital structure is found at Altius Telecom, Embassy Off.REIT, Mindspace Busine, Kalpa Commer., and the rest. IDream Film, iSERA Lifescienc, Focus Suites Sol, and Amsons Apparels do not qualify for capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is iSERA Lifescienc at 3875.14%, while the peer with the lowest is Sagility at -5.97%. iSERA Lifescienc's return significantly surpasses all peers. Additionally, the six-month return is negative for Sagility and Kalpa Commer.

How big is iSERA Lifescienc?

As of 14th August, iSERA Lifesciences Ltd has a market capitalization of 121.00 Cr, classifying it as a Micro Cap company, with net sales of 19.37 Cr and a net loss of 0.08 Cr over the latest four quarters. Specific values for Shareholder's Funds and Total Assets are not available.

As of 14th August, iSERA Lifesciences Ltd has a market capitalization of 121.00 Cr, classifying it as a Micro Cap company.<BR><BR>In the latest four quarters, iSERA Lifesciences Ltd reported net sales of 19.37 Cr. The net profit for the same period was a loss of 0.08 Cr.<BR><BR>The reporting period for the balance sheet data is the latest annual period. However, specific values for Shareholder's Funds and Total Assets are not available.

Should I buy, sell or hold Covidh Technologies Ltd?

Are Covidh Technologies Ltd latest results good or bad?

Covidh Technologies Ltd's latest results are concerning, showing a 69.34% decline in net sales quarter-on-quarter and a net loss, alongside a negative book value and a drastic drop in promoter holdings. The company's financial health indicates significant distress and a high-risk investment profile.

Covidh Technologies Ltd's latest results indicate significant financial distress. The company reported net sales of ₹1.11 crores for June 2019, which marked a staggering 69.34% decline quarter-on-quarter and a 91.95% drop year-on-year. Furthermore, it recorded a net loss of ₹0.06 crores, with negative operating margins and a negative profit after tax margin.<BR><BR>The company's financial health is further illustrated by its negative book value, with a price-to-book ratio of -24.71x, indicating that its liabilities exceed its assets. This situation has led to a complete absence of institutional investor interest, as there are no holdings from foreign institutional investors, mutual funds, or domestic institutional investors.<BR><BR>Additionally, there has been a dramatic decline in promoter holdings, dropping from 100% to just 3.57% in a short period, which is a significant red flag for potential investors. The extreme volatility in stock price, with a 756.85% increase over six months, does not reflect any underlying business improvement, but rather suggests speculative trading in a micro-cap stock with limited liquidity.<BR><BR>Overall, the financial results and the company's trajectory suggest a concerning outlook, characterized by a lack of sustainable profitability, significant operational struggles, and a high-risk investment profile.

When is the next results date for Covidh Technologies Ltd?

The next results date for Covidh Technologies Ltd is 10 February 2026.

The next results date for Covidh Technologies Ltd is scheduled for 10 February 2026.

How has been the historical performance of Covidh Technolog?

Covidh Technolog has experienced fluctuating financial performance, with net sales declining from INR 33.57 crore in March 2018 to INR 25.69 crore in March 2019, resulting in a profit after tax of -0.04 crore. The company faced rising raw material costs, leading to decreased profitability and negative earnings per share.

Answer:<BR>The historical performance of Covidh Technolog shows a fluctuating trend in net sales and profitability over the years.<BR><BR>Breakdown:<BR>Covidh Technolog's net sales have seen a decline from INR 33.57 crore in March 2018 to INR 25.69 crore in March 2019, following a peak of INR 35.89 crore in March 2014. The total operating income mirrored this trend, dropping from INR 33.57 crore in March 2018 to INR 25.69 crore in March 2019. The company faced significant raw material costs of INR 25.03 crore in March 2019, which contributed to total expenditure of INR 25.20 crore, resulting in a slim operating profit of INR 0.49 crore. However, the profit before tax turned negative at INR -0.02 crore in March 2019, leading to a profit after tax of INR -0.04 crore. This marked a notable decline from a profit after tax of INR 0.01 crore in March 2018. The earnings per share also reflected this downturn, falling to -0.04 in March 2019 from 0.01 in the previous year. Overall, the company's financial metrics indicate a challenging period, with decreasing revenues and profitability.

Is Covidh Technolog overvalued or undervalued?

As of October 24, 2025, Covidh Technolog is considered risky and overvalued with a PE ratio of 47.09 and negative financial metrics, contrasting sharply with its peers, despite a recent short-term stock performance that outpaced the Sensex.

As of 24 October 2025, Covidh Technolog's valuation grade has moved from does not qualify to risky, indicating a significant shift in its perceived investment quality. The company is currently assessed as overvalued, with a PE ratio of 47.09, a negative Price to Book Value of -6.59, and an EV to EBIT of -8.18. These ratios highlight the company's financial struggles and lack of profitability, which are concerning for potential investors.<BR><BR>In comparison to its peers, Covidh Technolog's valuation metrics are starkly unfavorable. For instance, Altius Telecom, categorized as very attractive, boasts a PE ratio of 55.11, while other peers like Embassy Office REIT and Mindspace Business have PE ratios of 25.69 and 55.87, respectively. The stark contrast in these ratios underscores Covidh Technolog's precarious position in the market. Additionally, while the company's stock has outperformed the Sensex in the short term, with a 1-month return of 30.67% compared to the Sensex's 3.05%, the overall valuation concerns suggest that this momentum may not be sustainable.

Who are the top shareholders of the Covidh Technolog?

The top shareholder of Covidh Technolog is Ganapa Narsi Reddy, who owns 100% of the promoter shares. There are no pledged holdings, mutual funds, foreign institutional investors, or significant public shareholders involved.

The top shareholder of Covidh Technolog is Ganapa Narsi Reddy, who holds 100% of the promoter shares. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. Additionally, there are no significant public shareholders or individual investor holdings reported.